Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
出版年份 2019 全文链接
标题
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
作者
关键词
-
出版物
NATURE MEDICINE
Volume 25, Issue 5, Pages 751-758
出版商
Springer Science and Business Media LLC
发表日期
2019-04-23
DOI
10.1038/s41591-019-0424-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- (2017) Christophe Massard et al. Cancer Discovery
- Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
- (2016) Jennifer J. Wheler et al. CANCER RESEARCH
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
- (2016) M. Schwaederle et al. MOLECULAR CANCER THERAPEUTICS
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
- (2016) Maria Schwaederle et al. JAMA Oncology
- Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial
- (2015) J. Rodon et al. ANNALS OF ONCOLOGY
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Somatic mutation in cancer and normal cells
- (2015) I. Martincorena et al. SCIENCE
- A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
- (2015) Vladimir Lazar et al. Oncotarget
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
- (2015) Filip Janku et al. Oncotarget
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
- (2014) Filip Janku et al. Cell Reports
- Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway
- (2013) Floyd Christopher Holsinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations
- (2013) P. Ganesan et al. MOLECULAR CANCER THERAPEUTICS
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Emerging landscape of oncogenic signatures across human cancers
- (2013) Giovanni Ciriello et al. NATURE GENETICS
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors
- (2012) Ignacio Garrido-Laguna et al. PLoS One
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
- (2011) Filip Janku et al. PLoS One
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- (2010) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic
- (2010) S. Koscielny Science Translational Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now